1. The risk of pregnancy should be considered when prescribing opioids to women of childbearing age, and women of childbearing age should be informed of the risk of opioid use during pregnancy.

2. If opioids are prescribed to women of childbearing age, consider contraceptive treatment and pregnancy testing as a part of ongoing monitoring.

3. All patients should receive early screening for substance use disorder. When indicated, patients should receive in-practice intervention and be referred to appropriate treatment for a full, individualized assessment to determine the intensity and duration of care.

4. When opioids are prescribed during pregnancy for chronic pain, consultation with a high-risk obstetrics specialist as well as a pain specialist should be considered. Consider co-prescribing naloxone for patients with increased risk of opioid overdose.

5. Patients should be counseled to store medications securely, never to share them with others, and to properly dispose of medications.

The use of opioids for the treatment of pain in women of childbearing age:

1. Consider nonpharmacologic therapies and/or nonopioid pain medications, such as acetaminophen, when providing pain control to pregnant patients experiencing acute pain. Use of non-steroidal anti-inflammatory drugs (NSAIDs) during the first and third trimester (greater than 32 weeks gestation) may be associated with increased risk of fetal harm. Pregnant patients should be counseled not to use any NSAIDs, including over-the-counter, unless instructed. In the second trimester, NSAIDs may be considered for short courses, no more than 48 hours.

2. When opioids are considered for the treatment of acute pain in pregnant patients, the risks of such medications should be reviewed with the patient. These risks include preterm delivery, low birth weight, and neonatal abstinence syndrome (NAS).

3. If opioids are deemed necessary, use the lowest effective dose of immediate-release opioids, for no more than 3-7 days duration. Acute prescribing of opioids should never transition to chronic opioid administration without careful consideration.

4. For routine vaginal deliveries, nonpharmacologic and pharmacologic therapies are important components of postpartum care. A stepwise, multimodal approach emphasizing nonopioid medication as first-line therapy is safe and effective for vaginal births. Opioids are an adjunct for patients with uncontrolled pain despite adequate first-line therapy (i.e., nonopioid therapies as above). When prescribing opioids at postpartum discharge, a shared decision-making approach with the patient can optimize pain control while minimizing opioid use. Providers should use the lowest effective dose of immediate-release opioids and prescribe no more than 3-7 days duration. Long-acting or extended-release opioids are rarely indicated and should be avoided.

5. Non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen often provide sufficient pain control for women experiencing mild to moderate pain.

Pain management should focus on function rather than elimination of pain.

5. For routine vaginal deliveries, nonpharmacologic and pharmacologic therapies are important components of postpartum care. A stepwise, multimodal approach emphasizing nonopioid medication as first-line therapy is safe and effective for vaginal births. Opioids are an adjunct for patients with uncontrolled pain despite adequate first-line therapy (i.e., nonopioid therapies as above). When prescribing opioids at postpartum discharge, a shared decision-making approach with the patient can optimize pain control while minimizing opioid use. Providers should use the lowest effective dose of immediate-release opioids and prescribe no more than 3-7 days duration. Long-acting or extended-release opioids are rarely indicated and should be avoided.
1. The American Academy of Pediatrics advises providers to use the most comprehensive and current database of drugs that affect infants and/or lactation. This information is available at LactMed (http://toxnet.nlm.nih.gov).

2. Early breastfeeding by patients who received medications during delivery poses little risk to the infant. However, breast milk concentrations of codeine and morphine are equal to or somewhat greater than maternal plasma concentrations. Therefore, breastfeeding infants will be exposed to the opioids consumed by their mothers. Medications should be taken after breastfeeding, if possible, to maximize the time between taking the medication and breastfeeding, and thus minimize drug transfer through breast milk.

3. When considering treatment of acute pain in patients who are breastfeeding, nonopioid pain medication such as acetaminophen should be used first.

4. Maternal use of aspirin should be avoided, as aspirin persists in maternal milk for up to 24 hours, and neonatal metabolism is slow.

5. While limited use of codeine is likely to be safe in breastfeeding mothers, chronic use should be avoided.

6. Use caution when prescribing oxycodone to breastfeeding mothers, especially within two months of delivery, due to the risk of neonatal sedation.

7. Normeperidine can pass into breast milk, and the half-life of normeperidine is markedly prolonged in newborns. Therefore, repeated use of meperidine should be avoided.

8. Breastfeeding should be encouraged in the opioid-dependent mother maintained on buprenorphine or methadone if there are no medical contraindications to breastfeeding (including, but not limited to, HIV infection and/or active illicit drug use). Refer to existing breastfeeding guidelines and consult with a substance abuse treatment provider.

Learn more: opqic.org/omno

This publication was supported by cooperative agreements 6NU1CE003745-04 and 1NB01OT009219-01 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Department of Health and Human Services. This publication was issued by the Oklahoma State Department of Health, an equal opportunity employer and provider. 95,000 copies were printed by Mercury Press Plus at a cost of $3,950.78. A digital file has been deposited with the Publications Clearinghouse of the Oklahoma Department of Libraries in compliance with section 3-114 of Title 65 of the Oklahoma Statutes and is available for download at www.documents.ok.gov. Issued August 2019.